Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Rani Khatib"'
Autor:
Rani Khatib, Abigail Barrowcliff, Franki Wilson, Sidra Awan, Mutiba Khan, Stephen Wheatcroft, Alistair S. Hall
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
PurposeExtended dual antiplatelet therapy (DAPT) with ticagrelor and aspirin is recommended in selected cases after myocardial infarction (MI) but not widely deployed in practice. This study assessed an innovative, cardiology pharmacist-led virtual s
Externí odkaz:
https://doaj.org/article/e4b1737a8cd44868b2dc01f3ed9060c9
Autor:
Tauben Averbuch, Meisam Esfahani, Rani Khatib, James Kayima, Juan Jaime Miranda, Rishi K. Wadhera, Faiez Zannad, Ambarish Pandey, Harriette G. C. Van Spall
Publikováno v:
ESC Heart Failure, Vol 10, Iss 5, Pp 3152-3163 (2023)
Abstract Aims Heart failure with reduced ejection fraction (HFrEF) is treatable but guideline‐directed medical therapy (GDMT) may not be affordable or accessible to people living with the disease. Methods and results In this cross‐sectional surve
Externí odkaz:
https://doaj.org/article/5231924e88494bbf8c50fe40d6b28ef5
Autor:
Rani Khatib, Una Laverty, Gina Mcgawley, Alistair Hall, Chris Pepper, Ruth Price, Franki Wilson
Publikováno v:
BMJ Open Quality, Vol 12, Iss 2 (2023)
Background Medicines optimisation and adherence support are essential to secondary prevention after myocardial infarction (MI). Following successful implementation of a consultant pharmacist-led post-MI medicines optimisation clinic, the service was
Externí odkaz:
https://doaj.org/article/17450f4ee78f46cfbc430047d4c00bc1
Autor:
Rani Khatib, Alistair Hall, Michael Mansfield, Claire Burton, Mutiba Khan, Abigail Barrowcliff, Eunice Ikongo
Publikováno v:
Open Heart, Vol 9, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/305357f725ff49a886eeac4369cbeb85
Publikováno v:
BMC Cardiovascular Disorders, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background The ‘My Experience of Taking Medicines’ (MYMEDS) questionnaire is a self-reporting tool for identifying modifiable adherence barriers among individuals prescribed post-myocardial infarction (MI) secondary prevention medicines
Externí odkaz:
https://doaj.org/article/8dd603ad72c341a8b9f0850e1c4bc883
Publikováno v:
Open Heart, Vol 7, Iss 1 (2020)
ObjectivesIron deficiency (ID), with or without anaemia (IDA), is an important comorbidity in people with chronic heart failure (HF), but the prevalence and significance in those admitted with HF is uncertain. We assessed the prevalence of ID or IDA
Externí odkaz:
https://doaj.org/article/93f100c7c1ef4a7ba1ee14283b15eced
Autor:
Natalia Sofia, Stefan Mühlebach, Umberto M. Musazzi, Rani Khatib, José Manuel Martinez Sesmero, Hans-Peter Lipp, Jacqueline Surugue, Tiziana Di Francesco, Beat Flühmann
Publikováno v:
Pharmaceutics, Vol 13, Iss 7, p 1010 (2021)
We conducted research to assess hospital pharmacists’ familiarity with/interpretation of data requirements for the different regulatory approval frameworks and the impact of this on their approach to substitution in the formulary. The online questi
Externí odkaz:
https://doaj.org/article/b9e24f1eed5142b28728218642c8e1fb
Autor:
Faiez Zannad, Jacqueline Alikhaani, Sadegh Alikhaani, Javed Butler, Jason Gordon, Klaus Jensen, Rani Khatib, Lorenzo Mantovani, Robin Martinez, Wanda F. Moore, Masahiro Murakami, Lothar Roessig, Norman Stockbridge, Harriette G.C. Van Spall, Clyde Yancy, John A. Spertus
Publikováno v:
European Journal of Heart Failure. 25:478-487
Autor:
Ekaterini Lambrinou, Tina Birgitte Hansen, Mutiba Khan, Geraldine Lee, Rani Khatib, Ercole Vellone, Neil J Angus
Publikováno v:
Khatib, R, Angus, N, Hansen, T, Lambrinou, E, Vellone, E, Khan, M & Lee, G 2021, ' Perceptions of injectable therapies with cardiovascular benefit: an ACNAP survey of healthcare professionals to explore facilitators and barriers ', European Journal of Cardiovascular Nursing, pp. 1-8 . https://doi.org/10.1093/eurjcn/zvab106
Aims Injectable medicines are increasingly used to manage risk factors for cardiovascular (CV) events, such as dyslipidaemia and diabetes. These include proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and glucagon-like peptide-1 (GLP
Autor:
Ruth Price, Franki Wilson, Alistair Hall, Gina McGawley, Una Laverty, Chris Pepper, Rani Khatib
Publikováno v:
BMJ Open Quality. 12:e002152
BackgroundMedicines optimisation and adherence support are essential to secondary prevention after myocardial infarction (MI). Following successful implementation of a consultant pharmacist-led post-MI medicines optimisation clinic, the service was e